Startups
CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global and diversified biopharmaceutical company focused on developing and commercialising treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, DNA repair and acute or life threatening conditions. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL’s lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 and the US Food and Drug Administration in 2019 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information please go to http://www.clinuvel.com.
SCENESSE® and PRÉNUMBRA® are registered trademarks of CLINUVEL PHARMACEUTICALS LTD
SCENESSE® and PRÉNUMBRA® are registered trademarks of CLINUVEL PHARMACEUTICALS LTD
Overview
Location
Australia, Victoria, Melbourne
Employees
11-50
Phone
+61 3 9660 4900
Founded date
2001
Mentions in press and media 15
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 14, 2022 | Clinuvel Pharmaceuticals : Expands DNA Repair Program with 2nd Study | C O M P A N Y A N N O U N C E M E N T CLINUVEL Expands DNA Repair Program with 2nd DNA Repair Study CUV151 study to further evaluate afamelanotide Melbourne, Australia, 14 February 2022 ASX: CUV XETRA-DAX: UR9 ADR LEVEL 1: CLVLY EXECUTIVE S... |
| Jan 27, 2022 | Clinuvel Pharmaceuticals : Newsletter I - January 22 | Dear Shareholders, Friends, INTRODUCTION (Mr Malcolm Bull, Head of Australian Operations & Investor Relations) Happy New Year to all our stakeholders for 2022, a year in which CLINUVEL anticipates advances in our strategic initiatives a... |
| Jan 24, 2022 | Clinuvel Pharmaceuticals : SCENESSE Continued in Germany | C O M P A N Y A N N O U N C E M E N T SCENESSE® continued in Germany German insurance funds reimburse standard of care for EPP patients Melbourne, Australia, 24 January 2022 ASX: CUV XETRA-DAX: UR9 Level 1 ADR: CLVLY CLINUVEL today announce... |
| Dec 20, 2021 | Clinuvel Pharmaceuticals : Newsletter 6 - December 2021 | CLINUVEL Communiqué VI December 2021 Dear Shareholders, Friends, INTRODUCTION The last month has been a tragic lesson in the challenges posed by a global pandemic and the potential risks of inequality in access to healthcare. While we are p... |
| Nov 10, 2021 | Chair Address | C O M P A N Y A N N O U N C E M E N T Chair's Address Annual General Meeting 2021 Melbourne, Australia, 10 November 2021 ASX: CUV XETRA-DAX: UR9 NASDAQ INTERNATIONAL DESIGNATION: CLVLY My fellow shareholders, It is a pleasure to speak to yo... |
| Nov 8, 2021 | Media release - CLINUVEL Expands Pharmaceutical Portfolio | M E D I A R E L E A S E CLINUVEL EXPANDS PHARMACEUTICAL PORTFOLIO Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders Melbourne, Australia, 8 November 2021 ASX: CUV XETRA-DAX: UR9 NASDAQ ... |
| Oct 22, 2021 | Clinuvel Pharmaceuticals : First Patient Treated in CLINUVEL DNA Repair Study | C O M P A N Y A N N O U N C E M E N T FIRST PATIENT TREATED IN CLINUVEL DNA REPAIR STUDY Xeroderma pigmentosum (XP) patient dosed with afamelanotide in CUV156 Melbourne, Australia, 22 October 2021 ASX: CUV XETRA-DAX: UR9 NASDAQ INTERNATIONA... |
| Sep 22, 2021 | Clinuvel Pharmaceuticals : Confirms AGM Date | C O M P A N Y A N N O U N C E M E N T CLINUVEL CONFIRMS AGM DATE ASX: CUV Melbourne, Australia, 22 September 2021 XETRA-DAX: UR9 NASDAQ INTERNATIONAL DESIGNATION: CLVLY CLINUVEL PHARMACEUTICALS LTD (Company) today announces that in light of... |
| Aug 26, 2021 | Clinuvel Pharmaceuticals : Newsletter 4 - August 2021 | Dear Shareholders, Friends, INTRODUCTION With satisfaction, we look back at an eventful interval since we last communicated with you in News Communiqué III. Much progress was made on the pre-clinical, clinical, and commercial side of the Gr... |
Show more
Reviews 0
FAQ about CLINUVEL
When was CLINUVEL founded?
CLINUVEL was founded in 2001.
What has the press written about CLINUVEL?
Parsers VC has collected 15 articles mentioning CLINUVEL, among them “Clinuvel Pharmaceuticals : Expands DNA Repair Program with 2nd Study” (Feb 14, 2022) and “Clinuvel Pharmaceuticals : Newsletter I - January 22” (Jan 27, 2022).
Is CLINUVEL still active?
Yes, CLINUVEL is active; its latest activity on Parsers VC dates from Mar 4, 2024.